20:30 , Nov 30, 2018 |  BC Week In Review  |  Company News

Pfizer extends Lyrica exclusivity by six months in U.S.

Pfizer Inc. (NYSE:PFE) said FDA granted pediatric exclusivity to its blockbuster neurology drug Lyrica pregabalin, extending the product's patent protection by six months to June 30, 2019. Lyrica is approved in the U.S. to treat...
19:09 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D on Oct. 25 to support a Phase III trial of its self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase...
18:03 , Oct 25, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Bioinformatics screens A bioinformatics screen based on transcriptomic data sets could help identify new targets for approved drugs. The screen involved 3 steps: analyzing 2,052 genes from eight signaling pathways in data sets from...
13:27 , Oct 25, 2018 |  BC Extra  |  Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D to support a Phase III trial of its self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase III study of...
22:58 , Oct 11, 2018 |  BC Week In Review  |  Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial to treat moderate to severe essential tremor. Despite the miss, the company plans to start a Phase III trial...
21:55 , Oct 8, 2018 |  BC Extra  |  Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial to treat moderate to severe essential tremor. Despite the miss, the company plans to start a Phase III trial...
22:07 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other...
19:31 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting the USP5-CACNA1H interaction could help treat postsurgical pain. In a mouse model of incisional pain, shRNA targeting of USP5 or systemic knockout of CACNA1H decreased mechanical allodynia compared with...
20:05 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Diabetes Mouse studies suggest inhibiting CACNB3 could help treat Type II diabetes. In a genetic mouse model and a high-fat diet-induced mouse model of Type II diabetes, levels of CACNB3 were higher in pancreatic...
01:11 , Jun 29, 2018 |  BC Innovations  |  Tools & Techniques

QT replacement plan

FDA has completed validation of a preclinical assay system that could replace clinical QT testing, a move it hopes will lower development costs and reduce false alarms of arrhythmia risk. The question for drug developers...